Expression of resistance-related proteins in nephroblastoma after chemotherapy

M Volm1, J Mattern, G Stammler

  • 1German Cancer Research Center, Heidelberg, Germany.

Insights

Cytostatic treatment for nephroblastoma increased P-glycoprotein and altered glutathione peroxidase expression. Topoisomerase II levels decreased after treatment, suggesting chemotherapy impacts resistance proteins.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Nephroblastoma treatment response can be influenced by drug resistance proteins.
  • Understanding changes in these proteins after chemotherapy is crucial for treatment optimization.

Purpose of the Study:

  • To investigate the expression of key resistance-related proteins in nephroblastoma tumors before and after cytostatic treatment.
  • To determine if actinomycin D and vincristine therapy alters the expression of P-glycoprotein, glutathione S-transferase-pi, glutathione peroxidase, and topoisomerase II.

Main Methods:

  • Analysis of tumor tissue mRNA from 31 nephroblastoma patients (23 treated, 8 untreated).
  • Quantitative assessment of P-glycoprotein, glutathione S-transferase-pi, glutathione peroxidase, and topoisomerase II expression.
  • Confirmation of results using Polymerase Chain Reaction (PCR) and immunohistochemistry.

Main Results:

  • P-glycoprotein expression was absent in untreated tumors but increased in 12/23 treated tumors.
  • Glutathione peroxidase mRNA levels showed significant differences between treated and untreated groups.
  • Topoisomerase II expression was reduced in 18/23 treated tumors compared to untreated ones.
  • A significant positive correlation was observed between P-glycoprotein and glutathione peroxidase expression.

Conclusions:

  • Cytostatic chemotherapy with actinomycin D and vincristine significantly alters the expression of P-glycoprotein, glutathione peroxidase, and topoisomerase II in nephroblastoma.
  • These changes suggest a role for these proteins in mediating treatment response or resistance.
  • Further research is warranted to explore the clinical implications of these altered protein expressions.

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Kidney Transplant II: Surgical Procedure01:26

Kidney Transplant II: Surgical Procedure

Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living donor...
Kidney Transplant III: Nursing Management01:16

Kidney Transplant III: Nursing Management

Postoperative Nursing Management for Kidney Transplant PatientsPostoperative nursing management care includes monitoring the surgical site, encouraging early movement, and promoting lung health through breathing exercises. Nurses also administer prescribed medications like H2-blockers, such as famotidine, or proton pump inhibitors, like omeprazole, to help prevent gastrointestinal ulcers and bleeding. Fungal infections in the mouth and bladder can result from immunosuppressive and antibiotic...